Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101284 | 0.91 | HSD17B10 (0.43) | USP2HSD17B10TDP1 | |
| SCHEMBL8344012 | 0.81 | LMNA (0.35) | HSD17B10TDP1LMNA | |
| SCHEMBL16809992 | 0.81 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL29690346 | 0.81 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL8343333 | 0.80 | HSD17B10 (0.36) | HSD17B10TDP1 | |
| SCHEMBL10421554 | 0.79 | USP2 (0.33) | USP2 | |
| SCHEMBL29690178 | 0.79 | HSD17B10 (0.32) | HSD17B10 | |
| SCHEMBL13157497 | 0.79 | EGFR (0.30) | — | |
| SCHEMBL3278006 | 0.78 | EGFR (0.30) | — | |
| SCHEMBL4393736 | 0.77 | TSHR (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130029-A1 | GLYCEROL ETHERS VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOAMIX LTD. (IL) | 2009-05-21 | — | — | US | disclosed |
| US-7196052-B2 | Fragrance composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20030216283-A1 | Fragrance composition | TAKASAGO INTERNATIONAL CORPORATION | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216283-A1 | Fragrance composition | FAAH2, FAAH, DGAT1 | USP2 3566/4885HSD17B10 41/4885TDP1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.